I just came across this scan called "Combidex Nano MRI" and was wondering if anyone here has any recent experience with it.
Age 52 at Diagnosis, 7/2019, PSA 5.5
Biopsy 4/12 positive, G8 all 4 cores (80%, 90%, 5%, 25%)
RALP 10/2019 G9 (4+5). SVI- EPE+ Clean margins. 9 nodes clean. T3aN0M0
3/20-4/20 SBRT 68 Gy (during Covid lockdown!)
1/20--7/20 Lupron
PSA: 11/19: 0.10, 1/20:0.11, 8/20: <0.02, 1/21: <0.02, 4/21: 0.07
Combidex is an iron oxide imaging agent that is injected and used with different scanning methods primarily to find lymph node Mets. It has been kicking around for a couple of decades and never gained traction in the US. The company filed for FDA approval in 2005, but never gained it. It has been available in several European countries and some PCa oncologists have sent patients overseas to get the scans that look for Mets.
In the late 1990’s there was a method developed called Prosta-Scint that used Combidex as the imaging agent. I know one man that was having trouble finding PCa after more than a dozen biopsies and steadily increasing PSA. He went to Amsterdam for the scan. At about the same time my urologist was a lead author on a study that showed Prosta-Scint was ineffective. Also about that time, the iron oxide was in very limited supply and the various companies looked for other agents to use.
NCBI has a paper from 2018 that describes the nano MRI that you reference. It basically says that Combidex is again of interest and companies are studying it. I am not aware of it being available in the USA.
PSA 59 on 8-26-2010 age 60. Biopsy 9-8-2010 12/12 positive, 20-80% involved, PNI in 3 cores, G 3+3,3+4,and 4+3=G7, T2b.
Eligard and Jalyn started on 10-7-2010. IMRT to prostate and lymph nodes started on 11-8-2010, HDR Brachytherapy December 6 and 13, 2010.
PSA < .1 since February 2011. Located in Cumming Georgia north of Atlanta
In the late 1990’s there was a method developed called Prosta-Scint that used Combidex as the imaging agent. I know one man that was having trouble finding PCa after more than a dozen biopsies and steadily increasing PSA. He went to Amsterdam for the scan. At about the same time my urologist was a lead author on a study that showed Prosta-Scint was ineffective. Also about that time, the iron oxide was in very limited supply and the various companies looked for other agents to use.
NCBI has a paper from 2018 that describes the nano MRI that you reference. It basically says that Combidex is again of interest and companies are studying it. I am not aware of it being available in the USA.
PSA 59 on 8-26-2010 age 60. Biopsy 9-8-2010 12/12 positive, 20-80% involved, PNI in 3 cores, G 3+3,3+4,and 4+3=G7, T2b.
Eligard and Jalyn started on 10-7-2010. IMRT to prostate and lymph nodes started on 11-8-2010, HDR Brachytherapy December 6 and 13, 2010.
PSA < .1 since February 2011. Located in Cumming Georgia north of Atlanta
There seems to be some renewed interest, e.g. a Dutch study:
Accuracy of lymph node imaging in prostate cancer: a prospective cohort study to determine the concordance between 68 Ga-PSMA-PET-CT and ferumoxtran-10 magnetic resonance imaging (nano-MRI) (2020)
"Schlussfolgerungen/Conclusions With e-PLND only 14 % of +LNs were removed, showing the limitation of the ‘gold-standard’. In agreement with literature nano-(USPIO)-MRI detected more positive LNs with smaller diameter (<3.5mm)1 compared to 68Ga-PSMA-PET-CT. The missed +LNs were predominantly at a size which is at the edge or below the physical scanner-resolution."
Djin
69 yr at Dx, BPH x 20 yr, 9 (!) neg. Bx
2013 TURP for BPH (90-->30 g) no PCa
6-6-17 Nodule (R) + PSA on finasteride: 3.6-->4.3
Bx #10: 2/14 cores: G10 (5+5) 50% RB, G9 (4+5) 3% RLM, nodule neg
Bone scan, CTs: neg, 8-7-17 open RP @Duke, neg frozen sections, nerves spared
SM EPE BNI LVI SVI LNI(16): neg, PNI+, pT2c pN0 R0 MX, G9 (4+5) 5%, 64 g
Decipher 0.37 Low Risk, PSA 0.010 (3m)…0.020 (3y 7m)
Accuracy of lymph node imaging in prostate cancer: a prospective cohort study to determine the concordance between 68 Ga-PSMA-PET-CT and ferumoxtran-10 magnetic resonance imaging (nano-MRI) (2020)
"Schlussfolgerungen/Conclusions With e-PLND only 14 % of +LNs were removed, showing the limitation of the ‘gold-standard’. In agreement with literature nano-(USPIO)-MRI detected more positive LNs with smaller diameter (<3.5mm)1 compared to 68Ga-PSMA-PET-CT. The missed +LNs were predominantly at a size which is at the edge or below the physical scanner-resolution."
Djin
69 yr at Dx, BPH x 20 yr, 9 (!) neg. Bx
2013 TURP for BPH (90-->30 g) no PCa
6-6-17 Nodule (R) + PSA on finasteride: 3.6-->4.3
Bx #10: 2/14 cores: G10 (5+5) 50% RB, G9 (4+5) 3% RLM, nodule neg
Bone scan, CTs: neg, 8-7-17 open RP @Duke, neg frozen sections, nerves spared
SM EPE BNI LVI SVI LNI(16): neg, PNI+, pT2c pN0 R0 MX, G9 (4+5) 5%, 64 g
Decipher 0.37 Low Risk, PSA 0.010 (3m)…0.020 (3y 7m)
I just saw that the company, SPL Medical, that owns the agent has renamed it Ferrotran and is conducting trials in Europe at Radboud University. Sounds like what you are reporting, Djin.
PSA 59 on 8-26-2010 age 60. Biopsy 9-8-2010 12/12 positive, 20-80% involved, PNI in 3 cores, G 3+3,3+4,and 4+3=G7, T2b.
Eligard and Jalyn started on 10-7-2010. IMRT to prostate and lymph nodes started on 11-8-2010, HDR Brachytherapy December 6 and 13, 2010.
PSA < .1 since February 2011. Located in Cumming Georgia north of Atlanta
PSA 59 on 8-26-2010 age 60. Biopsy 9-8-2010 12/12 positive, 20-80% involved, PNI in 3 cores, G 3+3,3+4,and 4+3=G7, T2b.
Eligard and Jalyn started on 10-7-2010. IMRT to prostate and lymph nodes started on 11-8-2010, HDR Brachytherapy December 6 and 13, 2010.
PSA < .1 since February 2011. Located in Cumming Georgia north of Atlanta
JNF said...
I just saw that the company, SPL Medical, that owns the agent has renamed it Ferrotran and is conducting trials in Europe at Radboud University. Sounds like what you are reporting, Djin.
Yes, that's where that study's investigators are based.
Djin
Post Edited (DjinTonic) : 5/18/2021 12:52:57 PM (GMT-6)
I have had the scan. As Prof Dr Barentz (sp?) explained to me during the infusion of the nono-iron, the company filing the FDA application did not even have a radiologist involved and made other errors. So Barentz had Radboud buy the rights ( a long, interesting story of that struggle).
PSA 5.3, RP 2009, Gl 3+4, neg margins, focal PNI, SRT 2012
PSA doubling time 13 mths, high 2.77
Nano-MRI 2014: 8 lymph node mets 4 to 9 mm, 6 para-aortic left, 2 common iliac right. Jan 2015 PSA 3.26, doubling time about 3 mths
Degarelix 4 mths 2-6/2015
FebMar 2015 IMRT 50 grays.
Dec 2016-now, Degarelix, PSA last 15 times: 0.02
PSA 5.3, RP 2009, Gl 3+4, neg margins, focal PNI, SRT 2012
PSA doubling time 13 mths, high 2.77
Nano-MRI 2014: 8 lymph node mets 4 to 9 mm, 6 para-aortic left, 2 common iliac right. Jan 2015 PSA 3.26, doubling time about 3 mths
Degarelix 4 mths 2-6/2015
FebMar 2015 IMRT 50 grays.
Dec 2016-now, Degarelix, PSA last 15 times: 0.02
Prof Barentsz at Radboud University (The Netherlands)
specializes in radiology:
https://www.sciencedirect.com/author/7006484477/jelle-barentsz
DOB 1940
Dec 2012: GP felt a nodule and hardened prostate; confirmed by urologist
PSA: 11.9 ng/ml
Biopsy (3/1/2013): Several Gleason 4+5 loci (prostate=45 ml)
Stage: T2c
Transferred to RO
Casodex 1 month; then Lupron 5/13 through 12/14 (18 months total)
Jul-Sep 2013: SBRT (CyberKnife; 3 x 6.5 Gy) followed by IMRT (25 x 1.8 Gy)
Lowest PSA thereafter: 0.1 (3/20/15)
Latest (10/20) PSA = 1.3 ng/ml
specializes in radiology:
https://www.sciencedirect.com/author/7006484477/jelle-barentsz
DOB 1940
Dec 2012: GP felt a nodule and hardened prostate; confirmed by urologist
PSA: 11.9 ng/ml
Biopsy (3/1/2013): Several Gleason 4+5 loci (prostate=45 ml)
Stage: T2c
Transferred to RO
Casodex 1 month; then Lupron 5/13 through 12/14 (18 months total)
Jul-Sep 2013: SBRT (CyberKnife; 3 x 6.5 Gy) followed by IMRT (25 x 1.8 Gy)
Lowest PSA thereafter: 0.1 (3/20/15)
Latest (10/20) PSA = 1.3 ng/ml
CigaFred said...
I have had the scan.
When you did the scan do you remember what your psa was?
Age 52 at Diagnosis, 7/2019, PSA 5.5
Biopsy 4/12 positive, G8 all 4 cores (80%, 90%, 5%, 25%)
RALP 10/2019 G9 (4+5). SVI- EPE+ Clean margins. 9 nodes clean. T3aN0M0
3/20-4/20 SBRT 68 Gy (during Covid lockdown!)
1/20--7/20 Lupron
PSA: 11/19: 0.10, 1/20:0.11, 8/20: <0.02, 1/21: <0.02, 4/21: 0.07
See my profile, 2.77
Profile attached
PSA 5.3, RP 2009, Gl 3+4, neg margins, focal PNI, SRT 2012
PSA doubling time 13 mths, high 2.77
Nano-MRI 2014: 8 lymph node mets 4 to 9 mm, 6 para-aortic left, 2 common iliac right. Jan 2015 PSA 3.26, doubling time about 3 mths
Degarelix 4 mths 2-6/2015
FebMar 2015 IMRT 50 grays.
Dec 2016-now, Degarelix, PSA last 15 times: 0.02
PSA 5.3, RP 2009, Gl 3+4, neg margins, focal PNI, SRT 2012
PSA doubling time 13 mths, high 2.77
Nano-MRI 2014: 8 lymph node mets 4 to 9 mm, 6 para-aortic left, 2 common iliac right. Jan 2015 PSA 3.26, doubling time about 3 mths
Degarelix 4 mths 2-6/2015
FebMar 2015 IMRT 50 grays.
Dec 2016-now, Degarelix, PSA last 15 times: 0.02
Thank you Cigafred!
Age 52 at Diagnosis, 7/2019, PSA 5.5
Biopsy 4/12 positive, G8 all 4 cores (80%, 90%, 5%, 25%)
RALP 10/2019 G9 (4+5). SVI- EPE+ Clean margins. 9 nodes clean. T3aN0M0
3/20-4/20 SBRT 68 Gy (during Covid lockdown!)
1/20--7/20 Lupron
PSA: 11/19: 0.10, 1/20:0.11, 8/20: <0.02, 1/21: <0.02, 4/21: 0.07
Age 52 at Diagnosis, 7/2019, PSA 5.5
Biopsy 4/12 positive, G8 all 4 cores (80%, 90%, 5%, 25%)
RALP 10/2019 G9 (4+5). SVI- EPE+ Clean margins. 9 nodes clean. T3aN0M0
3/20-4/20 SBRT 68 Gy (during Covid lockdown!)
1/20--7/20 Lupron
PSA: 11/19: 0.10, 1/20:0.11, 8/20: <0.02, 1/21: <0.02, 4/21: 0.07